Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28922715 | 0.93 | ACE2 (0.44) | ACE2LMNAOPRM1 | |
| SCHEMBL27890636 | 0.86 | ACE2 (0.42) | ACE2LMNADNM1TSHRSMN1; SMN2 | |
| SCHEMBL383882 | 0.85 | — | — | |
| SCHEMBL6650910 | 0.82 | ACE2 (0.47) | ACE2LMNADNM1TSHROPRM1 | |
| SCHEMBL3163922 | 0.82 | ACE2 (0.47) | ACE2LMNADNM1TSHROPRM1 | |
| SCHEMBL2117705 | 0.81 | TSHR (0.39) | ACE2LMNATSHR | |
| SCHEMBL23924595 | 0.80 | ACE2 (0.39) | ACE2LMNADNM1TSHRSMN1; SMN2 | |
| SCHEMBL1005717 | 0.80 | ACE2 (0.39) | ACE2LMNADNM1TSHRSMN1; SMN2 | |
| SCHEMBL23924597 | 0.80 | ACE2 (0.39) | ACE2LMNADNM1TSHRSMN1; SMN2 | |
| SCHEMBL56652 | 0.79 | LMNA (0.50) | ACE2LMNADNM1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139926-A | Resin composition | 株式会社可乐丽 | 2024-06-04 | — | — | CN | disclosed |
| CN-118139909-A | Beta-methyl-delta-valerolactone based polymer | 株式会社可乐丽 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023068348-A1 | RESIN COMPOSITION | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068345-A1 | Β-METHYL-δ-VALEROLACTONE POLYMER | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| WO-2023068346-A1 | Β-METHYL-δ-VALEROLACTONE POLYMER | 株式会社クラレ | 2023-04-27 | — | — | WO | disclosed |
| CN-113322709-A | Shoe press belt and method for producing shoe press belt | 市川株式会社 | 2021-08-31 | — | — | CN | disclosed |
| CN-113321782-A | Shoe press belt and method for producing shoe press belt | 市川株式会社 | 2021-08-31 | — | — | CN | disclosed |
| CN-113322708-A | Shoe press belt and method for producing shoe press belt | 市川株式会社 | 2021-08-31 | — | — | CN | disclosed |
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-5675031-A | 4-hydroxy-2-cyclopentenone derivatives and anticancer agent and bone formation accelerator containing the same | TEIJIN LIMITED (JP) | 1997-10-07 | — | — | US | disclosed |
| EP-0448726-B1 | 2-SUBSTITUTED 2-CYCLOPENTENONE AND CARCINOSTATIC AGENT AND OSTEOGENESIS PROMOTER CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0659728-A1 | 4-HYDROXY-2-CYCLOPENTENONE DERIVATIVE AND CARCINOSTATIC AND OSTEOGENESIS PROMOTER CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1995-06-28 | — | — | EP | disclosed |
| US-5338844-A | 2-substituted-2-cyclopentenone compound and anticancer agent and bone formation accelerator comprising same as active ingredient | TEIJIN LIMITED (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5216183-A | Antitumor, anticarcinogenic agents; bone formation accelerators | TEIJIN LIMITED (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0448726-A1 | 2-SUBSTITUTED 2-CYCLOPENTENONE AND CARCINOSTATIC AGENT AND OSTEOGENESIS PROMOTER CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | CMA1, ACE, ALPI | ACE2 14/4885LMNA 1000/4885DNM1 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.